TPD & Induced Proximity Summit Leaderboard
  • Sunday, June 21, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 48

Author

Pharma Journalist 8887 posts 0 comments

FDA Approves Roche’s Gazyva for Lupus Nephritis with Streamlined Dosing

Oct 21, 2025
Roche announced that the U.S. Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who…
Read More...

Lundbeck and Contera Partner to Develop RNA-Based Neurology Drugs

Oct 21, 2025
H. Lundbeck A/S and Contera Pharma have announced a strategic research collaboration aimed at developing RNA-based medicines for serious neurological disorders with high unmet medical…
Read More...

FDA Approves Roche’s Gazyva for Lupus Nephritis, Offering New Hope for Patients

Oct 21, 2025
Roche announced that the U.S. Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who…
Read More...

GSK and ViiV Healthcare Pledge £6 Million to Boost Global Fight Against HIV, TB and Malaria

Oct 20, 2025
The Global Fund to Fight AIDS, Tuberculosis and Malaria has welcomed a new £6 million investment from GSK and its HIV specialist company ViiV Healthcare to strengthen community-led…
Read More...

Roche’s Giredestrant Combo Cuts Breast Cancer Progression Risk by Up to 62% in Phase III Trial

Oct 20, 2025
Roche announced positive Phase III results from its evERA Breast Cancer study, showing that the investigational drug giredestrant, when combined with everolimus, significantly improved…
Read More...

Merck Partners with U.S. Government to Slash IVF Drug Prices, Expand Access

Oct 17, 2025
Merck, through its U.S. and Canada healthcare division EMD Serono, has announced a landmark agreement with the Trump Administration to significantly expand access to in vitro…
Read More...

Tubulis Raises €308M to Advance Antibody-Drug Conjugate Pipeline

Oct 17, 2025
Tubulis, a German biotech company specializing in next-generation antibody-drug conjugates (ADCs), has secured €308 million (USD 361 million) in a major Series C financing round aimed…
Read More...

Novo Nordisk Acquires Rights to Zaltenibart in $2.1B Rare Disease Deal with Omeros

Oct 17, 2025
Novo Nordisk and Omeros Corporation have entered into a definitive agreement granting Novo Nordisk exclusive global rights to zaltenibart (formerly OMS906), a clinical-stage antibody…
Read More...

Adcytherix Secures €105M Series A to Advance Cancer Drug Pipeline

Oct 17, 2025
Adcytherix SAS, a French biopharmaceutical company developing next-generation antibody drug conjugates (ADCs), has closed a €105 million (US$122 million) Series A funding round — the…
Read More...

Minovia Therapeutics Wins FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome

Oct 16, 2025
Minovia Therapeutics Ltd., a clinical-stage biotech company focused on mitochondrial disease therapies, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan…
Read More...
Prev Next
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
In Vivo Cell Engineering & Gene Editing Summit
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Voro and Alloy Partner on Safer Cancer Immunotherapies
  • uniQure Reports Early Promise for Epilepsy Gene Therapy
  • Boltz and Takeda Expand AI-Powered Drug Discovery Efforts
  • SK Pharmteco Partners With OTXL for Rare Disease Therapies
  • Next-Generation GLP-1 Therapies Are Reshaping the Future of Obesity Treatment

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.